Care Homes: CCTV

Glyn Davies Excerpts

Wednesday 5th September 2018 Westminster Hall

[Glyn Davies (Montgomeryshire) (Con)]

I apologise that I will not be able to stay for the winding-up speeches, much as I would like to. I will have to depend on tomorrow’s Hansard to read the Minister’s response, which I am very much looking forward to. I have another meeting that I simply cannot avoid.

In the past, I spent some time working with a care home in an advisory capacity, helping them to deliver the effective and safe service that we all want. I was particularly involved with the development of an advocacy service for residents of care homes, and also a lay visitor scheme, which is hugely important. We are all aiming for the same result, as is today’s debate. We all want compassionate and effective care in our residential care homes that develops confidence for the people in them as well as a safe environment.

I congratulate my right hon. and learned Friend the Member for Beaconsfield (Mr Grieve) not only on securing this debate but on his comprehensive speech. I unashamedly inform him that I shall take some of what he has said today and claim it as my own in future speeches. He put a very comprehensive case and I agree with all of it, so there is no point in my repeating any of it except to say how much I agree.

I have two issues in mind. One is CCTV in communal areas, for which the case is strong, particularly in terms of protection and the promotion of welfare for residents, and also for issues such as the identification of personal property, which is often helped by CCTV. It promotes a general air of confidence. However, everyone must sign up to it. That is key. Everybody operating under CCTV knows perfectly well that it is there, which in itself develops a much higher standard and awareness of the way in which everyone should operate. There is a danger of a loss of trust if everybody is not aware. An absence of trust and a feeling that there is surveillance that people do not know about can cause great damage.

Cost is a concern. In my constituency of Montgomeryshire, there is huge pressure on residential care homes, although the adoption of the minimum wage has made a big difference. Quite a few care homes will not survive because, although the local authority pays a certain rate, access to private care is not how it would be in a more affluent part of the country, so there is a big dependence on local authority provision. However, the fees simply do not cover the cost. We must be aware of that so that we do not impose anything on care homes that reduces the number of care places available.

The issue of surveillance in private rooms is much more complex and controversial, but the reality is that it will happen more and more. There have been high-profile cases in which individual families have undertaken their own surveillance. I think that will increase because there have been high-profile incidents that highlighted poor care—others will undertake their own surveillance. The issue is how we manage it and the circumstances in which we consider it appropriate in private rooms. My instinct has always been that there should never be surveillance unless everybody within its view knows about it. That would lead to confidence and not cause damage.

Everybody wants safe and effective care in our care homes. I share the view of my right hon. and learned Friend the Member for Beaconsfield that introducing CCTV as a compulsory measure in all care homes at some stage would be a positive step in helping to achieve that.

Oral Answers to Questions

Glyn Davies Excerpts

Tuesday 19th December 2017 Commons Chamber

The Secretary of State was asked—

[Glyn Davies (Montgomeryshire) (Con)]

1. What the evidential basis is for his Department’s proposals on presumed consent for organ donation.

[The Parliamentary Under-Secretary of State for Health (Jackie Doyle-Price)]

An impact assessment has been published as part of the Government’s public consultation, and it suggests that moving towards an opt-out system for organ donation, as part of a wider communication and logistical package, can be associated with higher donation rates. The Government have invited submissions of further evidence, which we will consider carefully before responding. We have already received in excess of 2,000 responses since the consultation started last week.

[Glyn Davies]

As someone with a long-standing passion to increase the number of organs available for donation, I am encouraged by the Minister’s response. Does she think that the shift from the current voluntary system to one where the state makes decisions based on presumed consent had an impact on the reduction in the number of live donors over the past three years?

[Jackie Doyle-Price]

I part with my hon. Friend on his point about the state taking control through presumed consent. We are talking about a register from which people could physically opt out, rather than opt in. The issues about end-of-life consent will continue to be the same, and the next of kin will be a full consultee. As for live donation, the issues are complex, but one reason why we are seeing a decline is that the waiting lists for receiving an organ are coming down, which is reducing the need for live donors. We should keep a watching brief on that.

Colostomy Irrigation

Glyn Davies Excerpts

Thursday 2nd February 2017 Commons Chamber

[Glyn Davies (Montgomeryshire) (Con)]

When I secured this debate, I had not realised that it would be so close to World Cancer Day, which is on Saturday. Given the close connection between my subject and cancer, I could not have chosen a more appropriate date.

I begin by paying tribute to the colostomy nurses at the Royal Shrewsbury hospital, particularly Tracy Lunt, my personal stoma nurse, who helped me through a difficult time in my life and who encouraged me and introduced me to colostomy irrigation 14 years ago. I also thank colostomy nurse, Julie Powell, who telephoned me late one evening this week to help me to prepare after hearing that I had secured the debate. Colostomy nurses are special people, drawn to an unglamorous job that involves helping and encouraging people at the most difficult time in their lives. I imagine the subject of this debate is not often the subject of debate in Parliament. Madam Deputy Speaker, you have been an MP for longer than I have and may remember another occasion, but I do not. As far as I know, this may be the first time that this subject has appeared on the Order Paper.

I had best begin with some explanation of why the subject is of such importance to me and to many people—we do not know how many people because the subject is not talked about much. It is difficult to know how many people are irrigators, how many could be irrigators or how many would be if encouraged and helped by a sympathetic introduction process. At this point, I should introduce the background to my interest, which derives from bowel cancer. Colostomy irrigation has given me the freedom to live a full and active life. I will mention bowel cancer quite a lot because of its close connection with colostomy irrigation.

I am an ostomate—a person with a colostomy. I have owned my colostomy for almost 15 years, since undergoing an abdominoperineal resection to remove a cancerous tumour in 2002. I did not want a colostomy, but the alternative at the time was a far less attractive prospect. It was perhaps the most traumatic event in my life. I was uncertain about the future or, indeed, whether I even had a future at all. It certainly gave me a good understanding of how others feel in the same situation. I consider myself to have been extraordinarily lucky in that I made a full recovery.

One of the key reasons for my good luck and full recovery was that my cancerous colorectal tumour was diagnosed early in its development, before the disease had spread to my liver and elsewhere, when full recovery would be much less certain. Unsurprisingly, I have been a champion of early diagnosis ever since, and played a role in promoting bowel cancer screening programmes in Wales, when they were introduced a few years ago. The campaigning charity, Beating Bowel Cancer, is currently leading a campaign to reduce the age at which screening is offered from 60 to 50, as it is in Scotland. Instinctively, I support early screening, but realise that it serves no real purpose unless accompanied by the availability of sufficient endoscopy capacity.

Colorectal cancer, or bowel cancer, as it is commonly known, is one of the most common forms of cancer, with 110 new cases diagnosed every day. It is a traumatic shock for many when the tumour is first diagnosed, but the cancer is completely curable if caught early enough. It is possible to recover and do some fairly crazy things. For example, after recovery, I initiated the establishment of the Welsh parliamentary rugby team. In passing, I should say that, rather shamefully, our first game versus the Lords and Commons parliamentary team degenerated into a full-scale brawl, which received much coverage in the national media, and that is when I first met the hon. Member for Newcastle-under-Lyme (Paul Farrelly), a Labour MP. I went training with the late, great All Black Jonah Lomu, who had also suffered life-threatening illnesses, in preparation for that game. My friends, of course, think it was even crazier to seek election as a Member of Parliament.

The final introductory point I want to make concerns the title I have chosen for this debate. Until recently, I used the term “colonic irrigation”, like most people, but it is too often associated in the public mind with a lifestyle choice available in health and massage centres—a practice I have never really taken much interest in—so I now use the term “colostomy irrigation”, which has no such associations, and which accurately describes the process.

My speech has three main purposes. First, I want to explain what colostomy irrigation actually involves—what it is. Secondly, I want to explain why I decided to become an irrigator. Thirdly, I want to explain why I am seeking to raise the profile and awareness of colostomy irrigation, which I have been doing for 14 years. This Adjournment debate is the best platform to raise awareness that I have ever secured.

First, on the actual process, I am constantly surprised by how little is known about it. Even people suffering illnesses such as colitis or bowel cancer, who face the prospect of a permanent colostomy, seem to know little about the procedure. A colleague MP with a background in the clinical profession approached me today and said that not even all colostomy nurses know about it or encourage it. It seems not to be thought suitable for polite conversation; the human mind seems to go into “block” mode if the subject crops up.

However, the process is very simple. All it involves is hanging what is in effect a polythene bag, containing 1,000 to 1,500 ml of warm water, on some convenient hook—I usually use the bathroom curtain rail. One of the problems with smart modern hotels is that there are often no convenient hooks. Luckily, I am a farmer by background, so I am quite practical and naturally given to improvisation, and a coat hanger can be quite a handy hook. The water is then allowed to run by gravity, via a polythene tube, into that part of the lower bowel that my brilliant consultant surgeon left me with after surgery in 2002. Then, the water is allowed to just run out naturally; there really is not much more to it than that. The biggest downside is that the irrigator has to remain in the same location for about 45 minutes, but with complete freedom to read, write, telephone, prepare speeches for Adjournment debates, do sudoku, watch TV and a whole host of other things.

I want to emphasise that the process is not suitable for all ostomates. There can be insurmountable physical and, indeed, mental barriers that mean irrigation is just not possible. There are additional bits of equipment, such as commercially available water pumps, that replace simple gravity, but my experience is that they are not usually needed.

There is another point of interest here—certainly to me and, I think, to the Minister. I am told that while a very small percentage of ostomates in the UK irrigate—less than 5%—a very high percentage do so in the US. That is thought to be because all the equipment associated with wearing a colostomy bag is free in the UK but has to be paid for in the US—1,000 ml of water comes free.

Secondly, why do I irrigate myself? When I am asked, I give the same answer as when I am asked why I voted to leave in the EU referendum on 23 June—it could one day become a pub quiz question: what is the connection between the EU referendum and colostomy irrigation?—and that answer is to take back control. I wanted to take back control of my own body and not allow my colostomy to rule my life, which it could well have done. I did not want to have to wear a colostomy bag. I wanted to continue my public life without being concerned about an “active” colostomy at inconvenient times. I can irrigate when and where it is convenient for me to do so. I take the decisions, not my colostomy. I have—as, indeed, have all the other ostomates who irrigate—genuinely taken back control.

Thirdly, I turn to the main reason why I am raising the issue in this debate. Having experienced the extra freedom, self-confidence and control that colostomy irrigation gives me, I want to encourage other ostomates to think about doing the same. I must emphasise that it does not work for every ostomate, and, in any case, it is a matter of choice. It is not a question of what one should do; it depends on what one can do and what one wants to do. All I want to do is to suggest to ostomates who have never thought about irrigation to consider it. There will be a few uncertain days to begin with while the body familiarises itself with the process, but, with the guidance and encouragement of their stoma nurses, they too may find the freedom and control that colostomy irrigation brings.

The background to every colostomy is some form of clinical need, involving fear, trauma, great uncertainty, great need for relief from pain or even simply a desire to stay alive. World Cancer Day is on Saturday, and I am really grateful that I have had the chance to play a small part in making life better for at least some of those who are suffering from the implications of bowel cancer.

Public Administration and Constitutional Affairs Committee

Glyn Davies Excerpts

Thursday 2nd February 2017 Commons Chamber

[Mr Jenkin]

I confess I am not sighted on the proposal to cap litigation costs, but people resort to litigation only because they feel that their complaints are not being heard and that the problems they have identified in the service are not being addressed. People resort to litigation because they do not feel they are being told the truth. We know from our surgeries that most people who complain come in and say, “I only want to make sure this doesn’t happen to somebody else. I don’t want compensation.” Nevertheless, because that public-spirited attitude to complaining is so often rebuffed in the health service, people resort to litigation because they feel there is a cover-up.

In other fields, such as aviation and marine investigations, where this kind of investigative process is already established and is designed to find the causes of accidents without blame, there is far less resort to litigation at the outset. That does not preclude litigation in the final analysis, but discovering the truth without blame is the first step towards reconciliation.

[Glyn Davies (Montgomeryshire) (Con)]

I, too, greatly welcome this report, as do my constituents. That may seem surprising to some of my colleagues, as, of course, my constituency is in Wales, but all my constituents use hospitals in England for elective care and specialist care, so this is as important to the people of Wales as it is to the people of England. I have also been involved in many of the complaints. Does the Chair of the Committee acknowledge that, in the debates that he has had and in any follow-up debate that he might have, the position of Welsh constituents is key, because, although they are in another Administration as far as health is concerned, they depend on hospitals in England for treatment?

[Mr Jenkin]

I am most grateful to my Welsh hon. Friend for his question. It gives me an opportunity to highlight not only my agreement with the point that he makes, but that this is just about healthcare safety investigations in England. By pursuing this policy to set up HSIB, the Government have embarked on a very, very major and significant reform, which the health services in Scotland, Wales and Northern Ireland are certainly watching. I can assure my hon. Friend that they are being watched all over the world. Different countries in different jurisdictions have tried using various bodies to deal with this question. I do not think that any country before England has embarked on a reform of this scale and nature that has the capacity to transform safety investigation in a health system. I very much hope that Wales, Scotland and Northern Ireland will either set up their own equivalent of HSIB, or employ HSIB as the pinnacle of their investigation system as well. This matter is not something that necessarily needs to be devolved any more than the Air Accidents Investigation Branch of the Department for Transport.

Duodopa

Glyn Davies Excerpts

Tuesday 31st January 2017 Westminster Hall

[Mr Sharma]

I thank the hon. Gentleman for that intervention. I will come to that point later and respond to it.

That incorrectly assumes that the populations given the treatments are the same, which is not the case, as UK clinicians recommend Duodopa only if their patient cannot have deep brain stimulation or apomorphine. It is therefore illogical to say that deep brain stimulation or apomorphine is better value for money, as they are not suitable for direct comparison. As one person with Parkinson’s explained,

“I was at the end of the road before I had the Duodopa. I was literally wheeled into hospital to have the pump fitted and the Duodopa titrated, and about a week later I came out walking. I responded very quickly and noticed a huge improvement in my quality of life, and I always live in dread that it will be taken away.”

In these circumstances, I very much hope that something can be done to bring NICE to the mainstream view on the subject.

[Glyn Davies (Montgomeryshire) (Con)]

I have been involved for 15 or 20 years in supporting Parkinson’s disease patients or those living with Parkinson’s disease, and I think it is terrific that Members of Parliament initiate debates that raise its profile, raise awareness and ask the Minister to come before us and share views on where we are. I therefore congratulate the hon. Gentleman on securing and introducing the debate.

[Mr Sharma]

I thank the hon. Gentleman very much for his kind words and support.

This issue is of great importance to a relatively small number of people, but given that the treatment is currently available through NHS England, to withdraw it on the basis of an apparently flawed assessment would cause concern among a much wider community, as it might be seen as setting a precedent for decisions on other treatments in future. I would welcome the Minister’s comments on that.

Secondly, although it is well known that Duodopa is more expensive than some other therapies, it is not offered to everyone, and we believe that some of the economic modelling does not take into account the discounts that the manufacturer offers NHS England.

Duodopa was classified by the EU as an orphan treatment, meaning that the number of people for whom it is a suitable treatment is fewer than five in 10,000. There are known issues with using standard health technology assessment methodology to evaluate the efficacy of orphan medications—issues that are thought to place orphan medicines at a disadvantage compared with treatments in more widespread use.

In Scotland, Duodopa was considered by the Scottish Medicines Consortium and approved on the basis of its processes for evaluating orphan treatments. NICE concluded that for Duodopa the cost per quality-adjusted life year—the generic measure of the value for money of medical interventions, based on quality and quantity of life lived—was more than £500,000, but the SMC concluded that the cost was less than £80,000 when using a calculation appropriate for an orphan drug. Indeed, a recent parliamentary question revealed that, from July 2015 to December 2016, just 75 people in England had been given Duodopa.

Thirdly, if Duodopa treatment is denied, that means there will be increased costs from social care and other things on which the person with Parkinson’s will become dependent, to say nothing of the quality of life or dignity of that person, which cannot be so easily reduced to a monetary figure. As Professor David Burn, the national clinical director for the UK Parkinson’s Excellence Network, has commented:

“To not offer Duodopa as a treatment option is putting people with Parkinson’s in England at a disadvantage compared with other developed countries.”

I acknowledge that the Department of Health has no direct control over NICE, and I recognise that NICE needs to be independent of political considerations. However, since NHS England has in recent years determined that Duodopa can be routinely used for patients where appropriate, and both NHS Scotland and the SMC consider the treatment to be appropriate, NICE appears to be out of step with the prevailing opinion. Specifically, I look forward to the Minister’s guidance on what options are open to the Government when the basis of a proposal made by NICE is so flawed. The consequences of these proposals going ahead would be catastrophic for the dozens of people for whom this drug was their last resort, and would add pressure to an already buckling social care system.

[The Parliamentary Under-Secretary of State for Health (David Mowat)]

It is a pleasure to serve under your chairmanship this afternoon, Sir Edward. I add my congratulations to those of my hon. Friend the Member for Montgomeryshire (Glyn Davies) to the hon. Member for Ealing, Southall (Mr Sharma) on securing the debate. It is right that we use the opportunity to discuss matters such as this one in Parliament and to ensure that we, whether that be NICE or the Department, get this right.

May I start by agreeing with the hon. Member for Ealing, Southall? He made the point that it would be completely wrong for NICE to make an evaluation based on flawed data, flawed information and a flawed methodology. If that were the case—we will talk about that during the next few minutes—it would require action. He also made the point that it is right that we have a body such as NICE that attempts to validate the treatments that are available in a coherent and consistent way.

The hon. Gentleman mentioned the quality-adjusted life year issue. There has to be a method of comparing drugs that are available, for example, for Parkinson’s with those available for cerebral palsy or muscular dystrophy, and we have to be fair to the community as a whole. That is what the NICE process is intended to do. It is also important to make the point that at the moment, the drug is available in NHS England. It has been commissioned since 2015 by the specialised commissioning team. That will continue—the updated NICE guidance will not change it—until NHS England’s specialised commissioning group makes a different decision, if that is what happens.

I will make a few points about Parkinson’s first of all. We know that it is a terrible, progressive disease and that there is no real understanding of what causes it. The occurrences of it are rising. Some 130,000 people in England have been diagnosed with Parkinson’s disease, which is caused by the death of a type of cell—those containing dopamine—in our brains. As the hon. Gentleman said, the disease causes tremors, stillness, slow movement, speech impediment and so on. Of those 130,000 people who are suffering from Parkinson’s disease, something like one in 1,500 are given Duodopa. There are currently 75 people in England who receive it, and the cost is roughly £28,000 for each of them.

The process is that when a diagnosis of Parkinson’s is made, NHS England typically refers the patient to a specialist centre for neurological care and an evaluation. A set of processes are carried out by the neurosurgeons in an attempt to remedy the dopamine issue that will have caused the Parkinson’s. The typical and main treatment is a drug called levodopa, but for a number of people there are side effects and it eventually stops working. As a follow-up remedy, as the hon. Gentleman said, either apomorphine, brain stimulation or Duodopa is prescribed, or a combination of those three things. How they interact with one another is quite complex, but those are the typical prescriptions if the main treatment is not successful.

As I said, the cost of Duodopa is something like £28,000 per patient per year, and 75 people are receiving it, so that is around £2 million a year, which is not massive in the great context of NHS spend. Nevertheless, it is important that we compare it with other treatments and make sure that it is the most effective for patients. That is what NICE has done. It had previous guidance on the treatment of Parkinson’s from 2006 and over the past year or so has produced draft guidelines, which the hon. Gentleman referred to, on the use of the drug. Those guidelines were put out to consultation, which closed in November. It is true, as the hon. Gentleman said, that those draft guidelines said that in NICE’s view, at no stage in the treatment is Duodopa to be recommended. The reason given was that, under NICE’s evaluation criteria, the cost of the drug is too high.

I have the NICE report in front of me, and the actual analysis is quite complex. The hon. Gentleman said that the report talks about the figure of £500,000—or alternatively £80,000, as I think I heard him say—per quality-assisted life year. I think it also comes up with lower numbers, but the truth is that it does not come up with a number that is anything close to the normal threshold at which a drug is approved for use, which is typically £20,000 to £25,000 per quality-assisted life year. The hon. Gentleman mentioned the methodology that was used. The consultation process drew in points from members of the public, from the profession and indeed from the company that markets the drug, which did say that there were methodology issues—I think it used the phrase “issues with the mathematics”. Those points will all be referred to the NICE committee and will be taken into account if and when the final analysis is confirmed or changed.

However, I will say that a quality-assisted life year figure in the order of £80,000 is quite a long way away from where it needs to be. There are various remedies for that. In similar debates I have made the point that one option is for the drugs companies involved to review their pricing. These things are not necessarily set in concrete. When they price a drug they are doing two things, and the cost of actually manufacturing the drug is often quite small compared with the invested intellectual capital that they are trying to recover. There is a choice, because if the drug is not prescribed they are not recovering either of those costs. I simply make the point that there is an opportunity for the company to do that.

As the hon. Gentleman said, it is true that NICE’s recommendation is that a combination of apomorphine and deep brain stimulation is more effective as a treatment and in terms of cost. We are having this debate on the draft guidance, and even if that guidance is confirmed, it will then have to go to the NHS England specialised commissioning group, which will have another opportunity to look at it in the round. As he said, Duodopa is a little unusual in that it is currently being prescribed. It is not as though it is a new treatment—it was prescribed in advance of the NICE recommendation.

I will say a little bit about NICE. It is very easy to knock it and say, “These guys don’t know what they’re doing. They don’t understand what is going on. It is obvious that if they were a bit more diligent or a bit better trained they would not have given this answer.” I looked at who was on the committee for the Parkinson’s guidelines. There were 18 people; it comprised consultant neurosurgeons, neurology pharmacists, people from patient groups and physiotherapists, so there were a number of people with a great deal of experience in managing Parkinson’s disease. It is important that the decisions on how we make drugs available are made by scientists, based on rigorous criteria and an attempt to look at the science rigorously, and not by Members of Parliament, as I think everybody in the Chamber would agree.

[Glyn Davies]

I intervene only to reinforce the Minister’s point. I remember being involved in campaigning against NICE and calling it out for everything I could when bowel cancer drugs were not available. That was driven by my personal interest, but in time I have come to realise—partly because my son who works for a drug company lectures me about this—that the principles behind NICE are absolutely vital. If we ever move away from that, we will finish up in a complete free-for-all, with all sorts of pressure and inducements from Members of Parliament not to follow proper procedure.

[David Mowat]

I can only concur that many of us benefit from lectures from our children, and it is nice to know that my hon. Friend does. I agree with the point made by the hon. Member for Ealing, Southall. If NICE has made a mistake, if something has been wrong in its analysis—this is why draft guidelines are published—and if things are brought to its attention that are not adequately reflected in its work, it has the opportunity to change that and will do so. Given the points that we have just heard, that is the right process.

When the finalised position is established, NHS England will consider whether to accept the NICE guidance. It will make a decision on what it does regarding the cohort that receive the drug and new patients, for whom there is potentially a difference in treatment. That process is many months away, frankly. It will not occur until NICE has finalised its guidance and published the complete position.

I finish by agreeing with the intervention made by my hon. Friend the Member for Montgomeryshire. These decisions are very difficult. Only 75 people receive the drug, but for them it is potentially life-changing, as it would be for the people who will need it in future, and I do not want to underestimate that. I can only repeat the points made in the NICE guidance; it believes that there are other equally effective treatments, such as a combination of apomorphine and brain stimulation. I am not a clinician, so it is not possible—and not right—for me to have a view on that, other than to say that until we are able to show that NICE has somehow been wrong in what it has done, it is right that we as a Parliament and as a group of MPs accept and respect that process, because we know that diligent scientists and clinicians have tried to get it right.

I thank the hon. Member for Ealing, Southall for raising this important subject; it is good that we have had the chance to talk about it today.

Question put and agreed to.

A&E Provision: Shropshire and Mid-Wales

Glyn Davies Excerpts

Wednesday 11th January 2017 Commons Chamber

[Glyn Davies (Montgomeryshire) (Con)]

Thank you, Madam Deputy Speaker, for allowing me to speak on what is the most important and concerning issue in my constituency over recent years—and it is certainly particularly acute at this moment. I would love to make several points and make a full speech at some stage, but on this occasion, I shall restrict myself to making just three points that I hope the Minister will address.

First, I emphasise the importance of the title chosen for the debate: A&E Provision: Shropshire and Mid-Wales. We so often assume that health is devolved, but the reality is that it is a devolved form of government, but it is not independence. The position is that in much of Wales, the system and the financial arrangements between the Governments allow for people to come to Shropshire. Nearly all Montgomeryshire’s patients who want secondary care, elective care and emergency care go to Shropshire. We depend absolutely on Shropshire, so I am hugely grateful that this debate is about Shropshire and mid-Wales.

My second point concerns the position of A&E units throughout Britain. We know perfectly well what the problem is: too many people are going to A&E without what we think of as reasons to need emergency treatment. We know that about 20% of the people who go to the A&E units in Shropshire should be going to the emergency centre because their conditions are life-threatening, with the remaining 80% going to the two centres in Telford and Shrewsbury. They will still effectively be A&E units, but they may well be referred to as urgent care centres. We know that that system will work.

This is my final point. Our two clinical commissioning groups set up a Future Fit programme board to make recommendations. It spent three years and £2 million—it could have been £3 million—producing a report which made it clear that the emergency centre should be based at Shrewsbury. It was a huge shock to my constituents when that recommendation was not accepted. Everyone is flabbergasted. I merely ask the Minister to give us some idea of how we can move forward from the shambles that is putting the interests and the care of my constituents—who are already having to travel for an hour to Shrewsbury for treatment—at the centre of the plans for Shropshire. That is vital to us. I hope the Minister will tell us how we can provide safe care for the people of Shropshire and the people of mid-Wales, which is our duty.

Bowel Cancer Screening Age

Glyn Davies Excerpts

Tuesday 8th March 2016 Westminster Hall

[Caroline Ansell]

I thank my hon. Friend for her moving contribution. Personal testimony highlights just why earlier intervention is vital—it can be life-saving.

[Glyn Davies (Montgomeryshire) (Con)]

My hon. Friend makes reference to personal experience. I would not be here today without an early diagnosis of the bowel cancer I suffered. I had an operation that left me with a stoma, and I am living proof that someone can make a 100% recovery and even become a Member of Parliament, if they work hard.

I hope my hon. Friend agrees that one of the big benefits of screening is not only the identification of blood as a possible sign of bowel cancer, but the raising of awareness. The truth is that it came as a huge shock to me, and I imagine that it comes as a huge shock to people who think they are invulnerable and do not believe that they could possibly be suffering from bowel cancer.

[Caroline Ansell]

My hon. Friend makes an apposite point, and I hope that, in a small way, this debate, underpinned as it is by personal testimony, plays a part in raising awareness. As I said at the beginning of my speech, the disease takes the second highest number of lives of all cancers.

Oral Answers to Questions

Glyn Davies Excerpts

Tuesday 13th October 2015 Commons Chamber

[Mr Skinner]

And Mr Speaker’s on my side, too.

[Glyn Davies (Montgomeryshire) (Con)]

15. What steps he is taking to increase levels of organ donation.

[The Parliamentary Under-Secretary of State for Health (Jane Ellison)]

Organ donation rates have increased by about 60% since 2008. The Government give about £60 million a year to NHS Blood and Transplant to support organ donation. NHSBT has a strategy, which it launched in 2013, to take us up to 2020 and increase that figure even further.

[Glyn Davies]

Does the Minister agree that one of the most effective ways of increasing organ donation is to ensure that the next of kin of every potential donor is offered a meeting with a specialist nurse in organ donation, irrespective of whether the potential donor carries a card?

[Jane Ellison]

My hon. Friend is absolutely right to highlight one of the principal difficulties we face, which is people not having a conversation about donation. Even if people are on the organ donor register, their wishes are sometimes overtaken by those of their families at that very difficult moment. He is right to highlight the brilliant work done by SNODs, as well as initiatives such as the one that will happen this Saturday, when the Daily Mail, together with the organ donor register, will produce a publication that will, we hope, stimulate thousands of conversations across the land. Having a conversation about consent is one of the ways we will crack this problem.

Oral Answers to Questions

Glyn Davies Excerpts

Tuesday 24th February 2015 Commons Chamber

[Mr Hunt]

I repeat:

“Claims of mass NHS privatisation were and are exaggerated”.

If the right hon. Gentleman does not like the reforms, let us look at a country that did not have them—Wales. The number of people waiting too long for A and E is nearly double that in England, the number of people waiting too long for urgent ambulances is nearly double that in England, and the number of people waiting for operations is 10 times that in England. That is our record—it is a record of success.

[Glyn Davies (Montgomeryshire) (Con)]

T3. Not enough GPs want to practise in rural Wales. I am told that one of the reasons is that GPs registered in England have to go through a bureaucratic process to be able to work in Wales. Will my hon. Friend the Minister work with the Welsh Government to ensure that we have a common registration process so that GPs can move between England and Wales without having lengthy, time-wasting new bureaucracy?

[The Parliamentary Under-Secretary of State for Health (Dr Daniel Poulter)]

I am very happy to look into that issue and to do what we can to support our NHS work force to move as freely as possible between England, Scotland, Wales and Northern Ireland. GP numbers in England have increased because we have protected the NHS budget, unlike in Wales, where it has been cut by the Labour Administration.

Francis Report: Update and Response

Glyn Davies Excerpts

Wednesday 11th February 2015 Commons Chamber

[Mr Hunt]

I know geography is a big issue, and the driving distance between Morecambe bay and Lancaster is a big challenge for the trust. I will look closely at that report, and I think Members in all parts of this House would welcome a commitment to avoiding scaremongering about local hospital services in the run-up to the election.

[Glyn Davies (Montgomeryshire) (Con)]

I represent a constituency in Wales, and look with some envy at the commitment to openness and transparency on both sides of this Chamber, and indeed the commitment to transparency and openness throughout the NHS in England following the Francis report and the Keogh review. What discussions can my right hon. Friend initiate, perhaps with the Opposition, to introduce the same level of transparency and openness in Wales so that my constituents in Montgomeryshire can also benefit?

[Mr Hunt]

I think it is very simple—there is a lot of agreement between us about what needs to happen. I recognise that the shadow Secretary of State is not personally responsible for what happens in Wales, but his party is, and a Keogh review of high mortality hospitals, a chief inspector of hospitals for Wales and a commitment to the whistleblowing measures announced today would do a lot to allay the concerns of my hon. Friend’s constituents that the lessons about openness are not being learned across the border.